NCT04895449View on ClinicalTrials.gov

Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

July 16, 2021

Primary Completion Date

November 2, 2022

Study Completion Date

November 8, 2022

Conditions
Covid19
Interventions
BIOLOGICAL

MVA-SARS-2-ST

i.m. vaccine administration

Trial Locations (2)

20251

CTC North, Hamburg

50937

Uniklinik Köln, Cologne

Sponsors
All Listed Sponsors
collaborator

German Center for Infection Research

OTHER

collaborator

Philipps University Marburg

OTHER

collaborator

Ludwig-Maximilians - University of Munich

OTHER

collaborator

IDT Biologika

UNKNOWN

collaborator

Clinical Trial Center North (CTC North GmbH & Co. KG)

OTHER

lead

Universitätsklinikum Hamburg-Eppendorf

OTHER

NCT04895449 - Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19 | Biotech Hunter | Biotech Hunter